<DOC>
	<DOC>NCT01395017</DOC>
	<brief_summary>The purpose of this study is to determine whether patients with locally advanced pancreatic cancer who receive dasatinib added to standard of care (gemcitabine) live longer, compared to patients who receive standard of care (gemcitabine) plus placebo; i.e. gemcitabine alone.</brief_summary>
	<brief_title>Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Histologic or cytologic documentation of unresectable adenocarcinoma of the pancreas. Recovery from toxicity of previous procedures to establish the diagnosis. ECOG PS 0 or 1. Adequate organ function. Evidence of metastatic disease. Previous radiotherapy or chemoradiotherapy. History of or current pleural effusion. History of significant cardiovascular disease. Clinically significant bleeding disorder or coagulopathy. Concomitant medication with strong CYP 3A4 inhibitor.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Pancreatic cancer</keyword>
	<keyword>Dasatinib</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>Locally advanced</keyword>
</DOC>